Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
44 hedge funds and large institutions have $46.6M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 6 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
151% more call options, than puts
Call options by funds: $321K | Put options by funds: $128K
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
16% more funds holding
Funds holding: 38 → 44 (+6)
33% less capital invested
Capital invested by funds: $69.1M → $46.6M (-$22.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.28M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.58M |
| 3 |
JP Morgan Chase
New York
|
+$270K |
| 4 |
Two Sigma Investments
New York
|
+$229K |
| 5 |
ACM
Aisling Capital Management
New York
|
+$228K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$9.81M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.38M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$1.48M |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$105K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$93K |
NBRV Hedge Fund Activity: Q3 2019 in Review
44 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2019, worth a combined $46.6M — down 33% from $69.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NBRV positions and 6 closed out — a net gain of 6 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.28M. The largest seller was Vivo Capital, exiting entirely with an estimated $9.81M sold.
- 44 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2019, up from 38 in Q2 2019.
- Funds reported $46.6M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2019, down 33% quarter-over-quarter.
- 12 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2019 and 6 closed out, a net change of +6 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2019 was Fidelity Investments, an estimated $3.28M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2019 was Vivo Capital, an estimated $9.81M sold.
Based on aggregated 13F filings for Q3 2019.